{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9","upperLimit":"65","value":"58"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"Progression-free survival is the defined as the time from study entry to disease progression (PD) or death. Patients without PD are censored at the date of last disease evaluation. PD is defined as a greater than 25% increase in serum IgM and 500mg/dL absolute increase from the lowest attained response value as determined by serum electrophoresis, confirmed by at least one other investigation, or progression of clinically significant disease related symptom(s).","dispersionType":"Inter-Quartile Range","groups":[{"description":"Carfilzomib, dexamethasone, rituximab\n\nDexamethasone: 20 mg IV on Days 1, 2, 8, 9, of 21 day cycle for cycles 1-6 20 mg IV on Days 1, 2 of 21 day cycles q 2 months for cycles 1-8\n\nCarfilzomib: 20 mg/m2 IV on Days 1, 2, 8, 9 of 21 day cycles for Cycle 1 36 mg/m2 IV on Days 1, 2, 8, 9 of 21 day cycles for Cycles 2-6 36 mg/m2 IV on Days 1, 2 of 21 day cycles q 2 months for Cycles 1-8\n\nRituximab: 375 mg/m2 IV on Days 2, 9 of 21 day cycles for Cycles 1-6 375 mg/m2 IV on Day 2 of 21 day cycles q 2 months for Cycles 1-8","id":"OG000","title":"Treatment Arm"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"4 years","title":"Time to Progression","type":"PRIMARY","unitOfMeasure":"months"}